{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/asthma/prescribing-information/azithromycin/","result":{"pageContext":{"chapter":{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin","depth":2,"htmlHeader":"<!-- begin field 71d57603-5b1f-4317-805d-abaa0075e7e4 --><h2>Azithromycin</h2><!-- end field 71d57603-5b1f-4317-805d-abaa0075e7e4 -->","summary":"","htmlStringContent":"<!-- begin item 72716269-d8f7-4d68-9988-abaa0075e756 --><!-- end item 72716269-d8f7-4d68-9988-abaa0075e756 -->","topic":{"id":"d631356f-d3a3-51fb-807c-5517c470a5af","topicId":"2a0a90e6-1c4e-4b6a-9ce2-3379dd122594","topicName":"Asthma","slug":"asthma","lastRevised":"Last revised in October 2020","chapters":[{"id":"c7185669-75fd-5c6e-b105-63a3237634ac","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"9fe1ab10-4b4d-5ba8-9ef0-00631cd00ea4","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"770d55df-2c61-5d1e-83d9-92b12ccae96a","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"d2031db2-44fd-55bb-b5c8-d085b387747a","slug":"changes","fullItemName":"Changes"},{"id":"a993bde1-1ac8-529e-8a3e-201a8c082ab2","slug":"update","fullItemName":"Update"}]},{"id":"eae8fe92-3941-512e-bcc6-f1e15157c1ae","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"8e125759-cd9d-510d-9659-3c2e77baa755","slug":"goals","fullItemName":"Goals"},{"id":"a6c91cd5-1ce2-5c60-86cc-341a9dccf3d4","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a5746054-2f36-5a42-9e7c-7af9107ad99b","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"5fd19cd9-6ac7-54c8-89be-817d58e41309","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"f7339086-c653-53dd-990c-6d470fa223b8","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"f43b79db-3c62-58ee-bb70-932e6613eea6","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"0d12a387-5436-5c75-92c0-189cb391ec7a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"8fbe04ed-5fd7-54c9-be84-6c959f75af3b","slug":"definition","fullItemName":"Definition"},{"id":"5cbe6206-f80c-5a71-8e4d-a4d44e392874","slug":"prevalence","fullItemName":"Prevalence"},{"id":"2fb588ab-6181-5aec-8a4a-fb368098329d","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"b786654f-5e6e-5e5f-9ead-abaca7f99ba5","slug":"prognosis","fullItemName":"Prognosis"},{"id":"c0b65c0b-957e-538e-83e9-5b4af2d8e6dd","slug":"complications","fullItemName":"Complications"}]},{"id":"574c6193-f36f-5bf7-946a-d8c688476131","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"351773e5-286c-5560-8402-79c2d92d4aa6","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"053272da-fea9-5df6-842a-0de682896aaf","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"7b632c20-012f-590e-a01e-cda5715d6f14","fullItemName":"Management","slug":"management","subChapters":[{"id":"f95fb73f-b749-53a5-b857-4d2bb9945667","slug":"newly-diagnosed-asthma","fullItemName":"Scenario: Newly-diagnosed asthma"},{"id":"2878c5f8-3e3f-52c8-a9bd-7988906b6f99","slug":"follow-up","fullItemName":"Scenario: Follow-up"},{"id":"2458c073-8efb-5a81-8bc4-9a543deab17d","slug":"acute-exacerbation-of-asthma","fullItemName":"Scenario: Acute exacerbation of asthma"},{"id":"45a1b06c-1e5d-56b4-8da7-a8abf4f6c7cc","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"52940123-8084-55c3-b593-cc9fe50daf8f","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"5eb1288c-29af-59c1-b623-bd0010732835","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"},{"id":"dc8f7545-ff7a-5bf1-8ac8-95161137fac5","slug":"inhaled-corticosteroids","fullItemName":"Inhaled corticosteroids"},{"id":"4d715496-c821-52e3-8ea0-d05cfb33d3eb","slug":"oral-corticosteroids","fullItemName":"Oral corticosteroids"},{"id":"d8174f33-d787-5076-88b5-f4c67df93128","slug":"leukotriene-receptor-antagonists","fullItemName":"Leukotriene receptor antagonists"},{"id":"a556cd4f-1851-52fd-a993-34e977a27fd2","slug":"muscarinic-agents","fullItemName":"Muscarinic agents"},{"id":"0cea3b69-b77b-505e-bded-6fceaca145df","slug":"theophylline","fullItemName":"Theophylline"},{"id":"550429f1-7cab-5f16-b476-e479d8084c03","slug":"cromones","fullItemName":"Cromones"}]},{"id":"76b3dfce-ba54-5456-a259-79b345a5e064","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"e31b3681-17cc-5ff2-ba28-d3b1fcb0a82c","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"2bcf3eeb-fd2e-5d40-a52f-da626afbbe01","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"14ea4312-4846-5381-a82c-dc6b03a60d04","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"e4987bc8-0a78-59eb-bfda-f9de7c9ee182","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"be4f3045-8192-53b7-81a3-b460bb2218bc","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"82ae443c-942c-5053-a988-38bce8dec570","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"efdf3cf8-dee5-5351-9d2d-346b4fdf9faf","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"fb9dc424-4306-54a1-b06b-1b01273ac473","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"d5a9fbbd-eee4-5704-86e8-f2424c69ca87","slug":"dose","fullItemName":"Dose","depth":3,"htmlHeader":"<!-- begin field 372933a5-91ad-4f6d-bdf1-abaa0075fff5 --><h3>Which dose should I give?</h3><!-- end field 372933a5-91ad-4f6d-bdf1-abaa0075fff5 -->","summary":"","htmlStringContent":"<!-- begin item e632ee11-f409-4584-9c9a-abaa0075ffce --><!-- begin field c1374b54-cb4e-435d-bf5b-abaa0075fff5 --><ul><li>For people aged 50–70 years who have ongoing symptoms despite use of high-dose inhaled steroids and at least one exacerbation requiring oral corticosteroids in the past year, prescribe:<ul><li>Azithromycin 500 mg once daily three times per week for a minimum of 6–12 months.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Smith, 2020</a>]</p><!-- end field c1374b54-cb4e-435d-bf5b-abaa0075fff5 --><!-- end item e632ee11-f409-4584-9c9a-abaa0075ffce -->","subChapters":[]},{"id":"f49df656-736f-56a5-ba95-b3c24f9221f1","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 3be47255-f70a-4022-bc1c-abaa00761628 --><h3>Contraindications and cautions</h3><!-- end field 3be47255-f70a-4022-bc1c-abaa00761628 -->","summary":"","htmlStringContent":"<!-- begin item 120107bb-f8d6-47e5-85d0-abaa007615fc --><!-- begin field 6eb41f56-6521-4a2f-a707-abaa00761628 --><ul><li><strong>Do not prescribe azithromycin in people:</strong><ul><li>With severe hepatic impairment.</li></ul></li><li><strong>Prescribe azithromycin with caution in people:</strong><ul><li>Who may be predisposed to prolongation of the QT interval. For example, people with:<ul><li>Congenital or documented acquired QT prolongation.</li><li>Currently receiving treatment with other active substances known to prolong the QT interval, such as antiarrhythmics of classes IA and III.</li><li>With electrolyte disturbance, particularly in cases of hypokalaemia and hypomagnesaemia.</li><li>With clinically relevant bradycardia, cardiac arrhythmia, or severe cardiac insufficiency, including Torsades de pointes.</li></ul></li><li>With mild to moderate hepatic impairment.</li><li>With severe renal impairment.</li><li>With myasthenia gravis — macrolides may aggravate symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 6eb41f56-6521-4a2f-a707-abaa00761628 --><!-- end item 120107bb-f8d6-47e5-85d0-abaa007615fc -->","subChapters":[]},{"id":"28f44cb1-d63d-5fac-a66a-334c42362153","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 88267bbf-fc0a-4029-82e3-abaa00762788 --><h3>Adverse effects</h3><!-- end field 88267bbf-fc0a-4029-82e3-abaa00762788 -->","summary":"","htmlStringContent":"<!-- begin item 4ed8c33a-0062-4cf3-950f-abaa00762769 --><!-- begin field 04a85ecb-af3d-46d4-8daa-abaa00762788 --><ul><li><strong>Gastrointestinal</strong> — diarrhoea, abdominal pain, nausea (very common); vomiting, dyspepsia (common); pancreatitis, pseudomembranous colitis (frequency unknown). For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li><li><strong>Nervous system</strong> — headache, dizziness, dysgeusia, paraesthesia (common); convulsions, hyperactivity, syncope, myasthenia gravis (frequency unknown).</li><li><strong>Psychiatric</strong> — nervousness (uncommon); aggression, anxiety (frequency unknown).</li><li><strong>Skin</strong> <strong>and subcutaneous tissue</strong> — rash, pruritus (common); Stevens-Johnson syndrome (uncommon); drug reaction with eosinophilia and systemic symptoms (DRESS), acute generalised exanthematous pustulosis (AGEP) (rare); toxic epidermal necrolysis, erythema multiforme (frequency unknown).</li><li><strong>Other common adverse effects include:</strong> <ul><li>Anorexia.</li><li>Arthralgia.</li><li>Deafness.</li><li>Fatigue.</li><li>Visual impairment.</li></ul></li><li><strong>Other adverse effects include:</strong><ul><li>Acute kidney injury.</li><li>QT interval prolongation.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 04a85ecb-af3d-46d4-8daa-abaa00762788 --><!-- end item 4ed8c33a-0062-4cf3-950f-abaa00762769 -->","subChapters":[]},{"id":"38667831-8f27-5400-9242-53a3e830c610","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 0294723a-034d-40f6-924f-abaa00763438 --><h3>Drug interactions</h3><!-- end field 0294723a-034d-40f6-924f-abaa00763438 -->","summary":"","htmlStringContent":"<!-- begin item 55cf8372-ffe8-43ab-81a7-abaa00763411 --><!-- begin field 6ca2bd59-d16c-418e-a756-abaa00763438 --><ul><li><strong>Antacids </strong>— plasma concentrations of azithromycin may be reduced. Simultaneous administration should be avoided — azithromycin should be taken at least 2 hours before, or 1 hour after antacids.</li><li><strong>Ciclosporin</strong> — azithromycin may increase cyclosporin levels. </li><li><strong>Cisapride </strong>— macrolides increase levels of cisapride, increasing the risk of arrhythmias (Torsade de pointes). Concurrent use is contraindicated.</li><li><strong>Colchicine</strong> — azithromycin slightly increases the levels of colchicine. Monitor for signs of colchicine toxicity (for example, nausea, vomiting, diarrhoea, myopathy, and pancytopenia).</li><li><strong>Digoxin</strong> — cases of increased digoxin levels have been reported. Monitor for signs of digoxin adverse effects (such as bradycardia). Monitor and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by azithromycin. Dose adjustment of edoxaban may be required.</li><li><strong>Rifabutin</strong> — azithromycin increases the risk of neutropenia when given with rifabutin. Monitor closely.</li><li><strong>Statins </strong>— there is a possible increased risk of myopathy.<ul><li>Advise the person to report any muscle pain, tenderness, or weakness.</li></ul></li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin</strong> — concurrent use may increase the international normalized ratio (INR). Consider increasing INR monitoring as this interaction appears to develop over the first 7 days.</li><li><strong>Drugs that prolong the QT interval</strong> (such as amiodarone, sotalol, and hydroxyzine) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is not recommended. If concurrent use is unavoidable consider ECG (electrocardiogram) monitoring.<ul><li>Concurrent use with domperidone, hydroxyzine, or mizolastine is contraindicated.</li></ul></li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, and short-acting beta-2 agonists) — hypokalaemia is a risk factor for QT prolongation.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Joint Formulary Committee, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/asthma/references/\">Preston, 2020</a>]</p><!-- end field 6ca2bd59-d16c-418e-a756-abaa00763438 --><!-- end item 55cf8372-ffe8-43ab-81a7-abaa00763411 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}